These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Cognitive impairment in a population-based study of patients with multiple sclerosis: differences between late relapsing-remitting, secondary progressive and primary progressive multiple sclerosis. Planche V; Gibelin M; Cregut D; Pereira B; Clavelou P Eur J Neurol; 2016 Feb; 23(2):282-9. PubMed ID: 25903918 [TBL] [Abstract][Full Text] [Related]
5. Contribution of cortical and white matter lesions to cognitive impairment in multiple sclerosis. Papadopoulou A; Müller-Lenke N; Naegelin Y; Kalt G; Bendfeldt K; Kuster P; Stoecklin M; Gass A; Sprenger T; Radue EW; Kappos L; Penner IK Mult Scler; 2013 Sep; 19(10):1290-6. PubMed ID: 23459568 [TBL] [Abstract][Full Text] [Related]
6. A one-year follow-up study of the Symbol Digit Modalities Test (SDMT) and the Paced Auditory Serial Addition Test (PASAT) in relapsing-remitting multiple sclerosis: an appraisal of comparative longitudinal sensitivity. López-Góngora M; Querol L; Escartín A BMC Neurol; 2015 Mar; 15():40. PubMed ID: 25886168 [TBL] [Abstract][Full Text] [Related]
7. Cognitive impairment and decline in different MS subtypes. Huijbregts SC; Kalkers NF; de Sonneville LM; de Groot V; Polman CH J Neurol Sci; 2006 Jun; 245(1-2):187-94. PubMed ID: 16643951 [TBL] [Abstract][Full Text] [Related]
8. Differences in cognitive impairment of relapsing remitting, secondary, and primary progressive MS. Huijbregts SC; Kalkers NF; de Sonneville LM; de Groot V; Reuling IE; Polman CH Neurology; 2004 Jul; 63(2):335-9. PubMed ID: 15277630 [TBL] [Abstract][Full Text] [Related]
9. Predicting Neuropsychological Impairment in Relapsing Remitting Multiple Sclerosis: The Role of Clinical Measures, Treatment, and Neuropsychiatry Symptoms. Lozano-Soto E; Cruz-López ÁJ; Gutiérrez R; González M; Sanmartino F; Rashid-Lopez R; Espinosa-Rosso R; Forero L; González-Rosa JJ Arch Clin Neuropsychol; 2021 May; 36(4):475-484. PubMed ID: 33067616 [TBL] [Abstract][Full Text] [Related]
10. Structural and cognitive correlates of fatigue in progressive multiple sclerosis. Andreasen AK; Iversen P; Marstrand L; Siersma V; Siebner HR; Sellebjerg F Neurol Res; 2019 Feb; 41(2):168-176. PubMed ID: 30513278 [TBL] [Abstract][Full Text] [Related]
11. Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis Patients with Very Mild Clinical Disability. Migliore S; Ghazaryan A; Simonelli I; Pasqualetti P; Squitieri F; Curcio G; Landi D; Palmieri MG; Moffa F; Filippi MM; Vernieri F Behav Neurol; 2017; 2017():7404289. PubMed ID: 28912625 [TBL] [Abstract][Full Text] [Related]
12. Circulating levels of interleukin-17A, tumor necrosis factor-alpha, interleukin-18, interleukin-10, and cognitive performance of patients with relapsing-remitting multiple sclerosis. Trenova AG; Slavov GS; Draganova-Filipova MN; Mateva NG; Manova MG; Miteva LD; Stanilova SA Neurol Res; 2018 Mar; 40(3):153-159. PubMed ID: 29297273 [TBL] [Abstract][Full Text] [Related]
13. Cognitive performance in relapsing remitting multiple sclerosis: a longitudinal study in daily practice using a brief computerized cognitive battery. Edgar C; Jongen PJ; Sanders E; Sindic C; Goffette S; Dupuis M; Jacquerye P; Guillaume D; Reznik R; Wesnes K BMC Neurol; 2011 Jun; 11():68. PubMed ID: 21649910 [TBL] [Abstract][Full Text] [Related]
14. The symbol digit modalities test and the paced auditory serial addition test involve more than processing speed. Berrigan LI; LeFevre JA; Rees LM; Berard JA; Francis A; Freedman MS; Walker LAS Mult Scler Relat Disord; 2022 Dec; 68():104229. PubMed ID: 36279599 [TBL] [Abstract][Full Text] [Related]
15. A preliminary validation of the brief international cognitive assessment for multiple sclerosis (BICAMS) tool in an Irish population with multiple sclerosis (MS). O'Connell K; Langdon D; Tubridy N; Hutchinson M; McGuigan C Mult Scler Relat Disord; 2015 Nov; 4(6):521-5. PubMed ID: 26590658 [TBL] [Abstract][Full Text] [Related]
16. Translational validity of PASAT and the effect of fatigue and mood in patients with relapsing remitting MS: A functional MRI study. Iancheva D; Trenova AG; Terziyski K; Kandilarova S; Mantarova S J Eval Clin Pract; 2018 Aug; 24(4):832-838. PubMed ID: 29611255 [TBL] [Abstract][Full Text] [Related]
17. Cognitive and Language Deficits in Multiple Sclerosis: Comparison of Relapsing Remitting and Secondary Progressive Subtypes. Ntoskou K; Messinis L; Nasios G; Martzoukou M; Makris G; Panagiotopoulos E; Papathanasopoulos P Open Neurol J; 2018; 12():19-30. PubMed ID: 29576812 [TBL] [Abstract][Full Text] [Related]
18. Olfactory function and cognition in relapsing-remitting and secondary-progressive multiple sclerosis. Carotenuto A; Costabile T; Moccia M; Falco F; Scala MR; Russo CV; Saccà F; De Rosa A; Lanzillo R; Brescia Morra V Mult Scler Relat Disord; 2019 Jan; 27():1-6. PubMed ID: 30273697 [TBL] [Abstract][Full Text] [Related]
19. Detection and quantification of regional cortical gray matter damage in multiple sclerosis utilizing gradient echo MRI. Wen J; Yablonskiy DA; Luo J; Lancia S; Hildebolt C; Cross AH Neuroimage Clin; 2015; 9():164-75. PubMed ID: 27330979 [TBL] [Abstract][Full Text] [Related]
20. Social Cognition Abilities in Patients With Different Multiple Sclerosis Subtypes. Henry A; Tourbah A; Chaunu MP; Bakchine S; Montreuil M J Int Neuropsychol Soc; 2017 Sep; 23(8):653-664. PubMed ID: 28656885 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]